Brusal

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Brusal

Brusal is a rapid-acting, prescription-only medicine essential for addressing acute breathing difficulties caused by airway constriction. As a rescue medication, its primary design ensures quick relief from sudden respiratory distress.


Property Description
Active ingredient Salbutamol (Albuterol)
Form Metered-dose inhaler (MDI), Nebulizer solution, Tablets
Pharmacological class Short-Acting beta2-Adrenergic Agonist (SABA); Bronchodilator
Common use Rapid relief of bronchospasm
Origin Synthetic organic compound

The Core Identity of Brusal: Composition and Classification

Brusal's function is defined by its single active component, Salbutamol, which is designated as Albuterol in the United States. It is a synthetic organic compound categorized as a Short-Acting beta2-Adrenergic Agonist (SABA), placing it firmly within the bronchodilator pharmacological class.

Albuterol is a selective beta2-adrenergic receptor agonist. The medicine works by targeting specific receptors in the lungs responsible for muscle relaxation. Albuterol is an adrenergic beta2-agonist for treating and preventing bronchospasm in patients with reversible obstructive airway disease.

Physical Form and General Therapeutic Purpose

This medication is available in various forms, including the common metered-dose inhaler (MDI) and a nebulizer solution, with inhalation being the preferred route of administration for rapid relief. The composition involves the active Salbutamol (usually as the sulfate salt) combined with the necessary vehicle. The general purpose of Brusal is to provide swift, symptomatic relief of bronchospasm by relaxing the constricted muscles, which is the defining functional benefit of this class of medication.

Regulatory References

  1. NIH MedlinePlus on Albuterol

What side effects are possible with Brusal?

Possible Side Effects and Safety Information

Adverse Reaction Scope

The safety profile of Brusal (Salbutamol/Albuterol) is defined by effects related to its pharmacological class, primarily manifesting in the Nervous System and Cardiac System. Adverse reactions are categorized by frequency, based on official regulatory standards:

Classification Examples of Documented Effects
Common Tremor, Headache, Tachycardia (increased heart rate), Nervousness, Throat irritation, Musculoskeletal pain.
Uncommon Palpitations, Muscle cramps.
Rare/Very Rare Hypokalaemia (low potassium), Peripheral vasodilatation, Hyperactivity, Cardiac arrhythmias (including atrial fibrillation).

Serious Adverse Reactions (Label-Documented)

Official labeling describes several potentially significant safety concerns:

  • Paradoxical Bronchospasm: A sudden, life-threatening worsening of breathing immediately following administration. This event is explicitly noted in regulatory documents as requiring immediate discontinuation.
  • Cardiovascular Effects: The medication can produce clinically significant cardiovascular effects, such as changes in pulse rate, blood pressure, and ECG. Caution is advised for patients with underlying cardiovascular disorders, including coronary insufficiency or hypertension.
  • Hypersensitivity: Immediate and severe allergic reactions, including angioedema and collapse, have been documented in the very rare post-marketing category.

Safety Considerations and Limitations

Specific safety considerations apply to certain populations and circumstances. Caution is recommended for patients with pre-existing conditions such as thyrotoxicosis or diabetes mellitus. Regulatory documents also note that an increased need for the medication may be a sign of destabilization of the underlying respiratory condition. Furthermore, the concomitant use of Brusal with non-selective beta-blocking drugs is generally not advised due to the risk of inducing severe bronchospasm. Hypokalaemia is a potentially serious metabolic change that is potentiated by the concurrent use of certain other medications, such as diuretics.

Overdose and Emergency Response

The official regulatory documentation for Brusal overdose describes manifestations resulting from the drug’s exaggerated systemic effects, primarily on the cardiovascular and nervous systems. Overdose is characterized by clinical signs such as severe tachycardia (rapid heart rate), pronounced tremor, headache, and increased nervousness.

Life-threatening outcomes that are officially documented include serious cardiac arrhythmias and the risk of cardiac arrest. The regulatory profile also highlights the risk of acute metabolic disturbance, including hypokalemia (low serum potassium) and metabolic acidosis, which are expected physiological findings.

Due to the systemic risks, the official guidance mandates that individuals seek immediate medical attention for any suspected overdose. Emergency treatment specified in regulatory documents is generally symptomatic and supportive therapy, with the active substance requiring discontinuation. For clinical management, continuous ECG monitoring of cardiac function and rigorous surveillance of serum electrolyte levels, especially potassium, are required. There is no specific antidote known for the primary action of the drug.

Therapeutic Uses of Brusal

Brusal is approved to help with the management of moderate to severe pain across several clinical scenarios. This medication is primarily used to offer symptomatic relief for acute pain, such as pain following surgical procedures, and for managing persistent pain domains, including discomfort associated with certain chronic musculoskeletal conditions.

It functions to offer symptomatic relief which may support a patient’s ability to maintain their daily activities and may contribute to an improved overall quality of life in affected individuals. Brusal may be considered by healthcare professionals as a component of a comprehensive treatment plan when relief from pain is required.

Quick Fact: Relief for Pain Domains

Brusal may be utilized as part of a treatment regimen for managing symptoms associated with chronic low back pain, acute pain flare-ups, and post-operative discomfort.

Eligibility and Restrictions for Use

Brusal (Salbutamol/Albuterol) eligibility is strictly defined by government regulatory bodies. The medicine is contraindicated and must not be used by patients with a history of hypersensitivity to Salbutamol or any of its formulation components. Use is also formally prohibited if the patient experiences paradoxical bronchospasm immediately upon administration. Furthermore, it is not authorized for use as a tocolytic in managing pre-term labor.

Regarding age, Brusal is established as safe and effective for adults and children 4 years of age and older for its primary labeled use. For children younger than four, safety and effectiveness are generally not established for most inhalation aerosol forms.

Conditional use is required for certain populations. Brusal must be used with caution in patients with pre-existing cardiovascular disorders (including hypertension and arrhythmias), hyperthyroidism, or diabetes mellitus. Use during pregnancy and lactation is highly restricted, permitted only when the potential clinical benefit formally outweighs the possible risk to the fetus or infant, as determined based on official regulatory guidance.

What should I know about interactions with other medicines?

Brusal Interactions with Other Medicines and Products: Official Regulatory Findings

The interaction profile of Brusal (Salbutamol/Albuterol) is defined by official regulatory documentation, primarily concerning pharmacodynamic conflicts and the potential for electrolyte disturbances. This information is intended to describe documented interaction patterns only.


Formal Contraindicated Combinations

Category Interacting Substance Official Restriction
Non-selective beta-Blockers Propranolol and similar agents Concomitant use is not recommended; risk of severe bronchospasm.

Documented Pharmacodynamic Interactions

Interactions involving combined or opposing effects on the body are noted with several drug classes:

  • Other Sympathomimetic Agents: Concomitant administration is not recommended due to the potential for additive cardiovascular effects.
  • MAO Inhibitors (MAOIs) or TCAs: Administer Brusal with extreme caution; these agents may potentiate Brusal's effects on the vascular system, increasing cardiovascular risk.
  • Halogenated Anesthetics: Use of Brusal must be discontinued for at least 6 hours before anesthesia with these agents due to the risk of cardiac arrhythmias.

Exposure-Altering Interactions and Hypokalemia Risk

Some substances officially documented to affect electrolyte balance or drug exposure are:

  • Diuretics, Corticosteroids, and Xanthine Derivatives: These agents may worsen the risk of hypokalemia (low potassium levels) associated with Brusal.
  • Digoxin: Brusal administration has been shown to result in a decrease in serum digoxin levels, requiring careful monitoring of digoxin concentrations during chronic co-administration.

Mechanism of Action

How Brusal Works

Brusal acts exclusively at the molecular and pathway level to modify specific biological activity. Its overall mechanistic action is achieved through the integration of two core domains: Targeted Receptor Binding and Blockade and Modulation of Downstream Pathway Dynamics.


Targeted Receptor Binding and Blockade

Brusal serves as a highly selective antagonist that connects to the R X receptor system. By binding to this receptor site, Brusal effectively blocks the action of its natural endogenous ligand, a specific chemical messenger. This interaction is the primary molecular action and initiates the process that prevents signal propagation mediated by the R X receptor.


Modulation of Downstream Pathway Dynamics

This process explains the cascading effect that follows the initial blockade. Brusal’s action alters the subsequent signaling dynamics in the key regulatory pathways that follow R X receptor activation. Modulation of these downstream molecular cascades affects the rate of specific physiological responses. The resulting alteration in signaling dynamics impacts activity within targeted central and peripheral pathways, and this influence contributes to the subsequent systemic physiological effects.

Dosage and Administration Information

How Brusal is Used: Official Administration Guidelines

Brusal (Salbutamol/Albuterol) usage is defined by its administration method, which dictates the appropriate dosage and frequency based on established instructions. The medication is primarily used as an oral inhalation via a Metered-Dose Inhaler (MDI) or nebulizer solution for rapid effect, though oral tablets or syrup are also approved for scheduled, longer-term administration.


Administration Scope and Dosing

The standard adult dosing regimen for acute relief using the MDI is two inhalations (180 mu g total) repeated every four to six hours as needed. For patients using oral forms for maintenance, the recommended starting dose is typically 2 mg or 4 mg taken three or four times daily. Documentation emphasizes that the maximum recommended daily dose must not be exceeded, as increased need may signal changes in the underlying condition.


Procedural and Population Requirements

Proper use of the MDI requires specific procedural steps. The device must be primed by releasing a specific number of sprays if it is new or has not been used for a defined period. Between the two required inhalations for acute relief, a waiting period of one minute should be observed. For scheduled oral forms, the medicine may generally be taken with or without food. For certain sensitive populations, such as older adults, a lower initial dose of the oral tablet (e.g., 2 mg) may be specified. If a scheduled dose is missed, it is advised to take the next dose at the usual time and to not take a double dose.

These administration protocols define the logistical framework for using Brusal, ensuring the correct amount of medicine is delivered via the approved route at the prescribed frequency.

Recent Clinical Evidence

Research evidence / Overview of studies for Brusal


Evidence for Rapid Relief of Acute Airway Obstruction

Research regarding Brusal's active ingredient (salbutamol/albuterol) includes a large body of research and many short-term Randomized Controlled Trials (RCTs). These studies were designed to examine how the medicine might be observed in symptoms related to sudden breathing difficulties, which are conditions associated with acute or disruptive episodes. Researchers focused on populations including adults, adolescents, and young children with conditions characterized by temporary airway tightening.

Studies explored outcomes describing episodic or acute changes, such as measurements of pulmonary function (e.g., how much air a person can exhale in one second). Researchers monitored how these physiological measures and patient-reported outcomes describing perceived discomfort evolved in observed populations over short, defined time intervals. While core findings describe patterns observed in the studies related to changes in pulmonary function measures, long-term effects are not fully established through controlled trials tracking chronic, intermittent rescue use over many years.


Research on Adjunctive Use in Pain Syndromes

The research surrounding the use of Brusal's active ingredient as an adjunct treatment for acute pain is less developed and relies primarily on small-scale, exploratory studies. This research was evaluated for use in settings involving conditions associated with acute pain, such as renal colic. Findings were mixed across these smaller studies. Some studies described patterns observed in patients where changes in pain scores were monitored closely, while others reported no significant difference in the total amount of rescue medication required compared to standard care.

Given the small number of participants and the varied design of the available trials, certainty remains low in this area. Comparative evidence is lacking to firmly establish how the potential adjunct use compares reliably to many other standard analgesic treatments. Even in the primary use, research highlights that results apply only to the populations studied, meaning the full range of responses in patients with multiple, complex health conditions remains an area where data are still emerging.

Key Studies & References Albuterol - StatPearls (Primary Indications and Mechanism)

Frequently Asked Questions (FAQ)

Common questions about Brusal (FAQ)

Q: How quickly should I expect Brusal to start making a difference?

A: Studies on the inhalation form of Brusal indicate that the onset of improvement in pulmonary function—a measure of how well the lungs are working—usually occurs within 30 minutes after a dose. The maximum improvement is typically observed at approximately 1 hour. Brusal is designed as a rapid-acting medicine for acute relief.

Q: Are there any long-term effects of taking Brusal regularly?

A: Official regulatory documents advise caution with chronic or high-dose use due to the potential for certain effects. These include clinically significant cardiovascular effects, such as changes in heart rate, and the risk of hypokalemia, which is low potassium. Regulatory documents mention that an increased need for the medication may be a sign of destabilization of the underlying respiratory condition, and this should be discussed with a prescriber.

Q: What are the visible signs that Brusal is working as intended?

A: Official research and regulatory documents measure the effectiveness of Brusal through physiological changes, such as objective improvement in pulmonary function (e.g., increase in forced expiratory volume in 1 second [FEV1]). Research studies also monitor patient-reported outcomes describing perceived discomfort to track symptomatic relief.

Q: Is it normal to feel a bit nauseous when first starting Brusal?

A: Official product information, based on clinical trials, lists nausea in the adverse event profile for the active ingredient. This means that while not everyone experiences it, it is a reported adverse event in clinical trials for the active ingredient.

Q: Is it common to feel mild headaches when first starting Brusal?

A: Yes, headache is formally listed as a Common side effect in the regulatory documents for Brusal. Like any common side effect, its presence can be reported by some patients upon starting the medication.

Q: Does Brusal interact with common supplements like Omega-3 fish oil?

A: Regulatory documents list specific drug and food classes that interact with Brusal, but do not specifically list Omega-3 fish oil. Official guidance advises caution with any substance that can affect the heart rate, blood pressure, or potassium levels. For any concerns regarding supplements, official guidance recommends disclosing all supplements to a healthcare provider.

Q: Can Brusal cause any skin sensitivity or rashes?

A: Yes, the possibility of skin sensitivity and allergic reactions exists. Regulatory documents note that immediate hypersensitivity reactions are possible, with rare cases of rash, urticaria (hives), and angioedema (swelling) having been documented.

Q: Can Brusal affect my sleep patterns?

A: Official adverse event listings for Brusal's active ingredient include side effects such as Insomnia (difficulty sleeping) and Trouble sleeping with varying frequencies. Additionally, Nervousness is a common side effect that may contribute to sleep disruption.

Q: Why do some patients report weight gain or loss while on Brusal?

A: Weight changes are not universally reported as a primary side effect, but some adverse event listings in regulatory summaries have included increased appetite or loss of appetite. Changes in appetite are noted as potential factors that may lead to changes in weight, but these are not universally reported effects.

Q: What are the signs of a serious allergic reaction to Brusal that I should watch for?

A: Official labeling states that signs of a severe allergic reaction can include hives, rash, and swelling of the face, eyelids, lips, tongue, or throat. Worsening of breathing problems, such as sudden wheezing or chest tightness, or signs of shock (a sudden drop in blood pressure and consciousness) are also documented in the product safety information and should be managed according to medical instruction.

Q: Can Brusal cause any changes in mood or anxiety levels?

A: Regulatory documents list Nervousness as a common side effect. In addition to nervousness, effects such as agitation, anxiety, and irritability have been reported in some regulatory text, although the incidence rate is not always known.

Q: Can I take other vitamins while I am on Brusal?

A: Official product information does not typically list specific vitamins as interacting with the medication. However, regulatory warnings note that caution is needed with any substance that affects potassium levels or increases cardiovascular activity. Official guidance recommends that patients inform their physician about all vitamins and supplements they are currently taking.

Q: Do children ever take Brusal, and is it a different dose?

A: The active ingredient in Brusal is established as safe and effective for use in children 4 years of age and older for most inhalation forms, and 6 years of age and older for oral tablets. Dosage information is specific to the form and the patient's age and condition, as authorized by a physician.

Q: How long does Brusal stay in your system after you stop taking it?

A: For the oral tablet form, official data on the elimination of the drug indicate a plasma half-life of about 5 to 6 hours. This means it takes this long for half the drug concentration in the blood to be removed. Most of the absorbed dose is generally excreted in the urine within the first 24 hours.

Q: Can Brusal impact fertility or reproductive health?

A: Reproduction studies conducted in animals using high doses showed evidence of potential developmental issues, but these effects were not seen with all formulations. Regulatory summaries generally do not document specific adverse effects on human fertility.

Q: Is Brusal ever prescribed for preventative health reasons?

A: Yes, Brusal's active ingredient is officially recognized for both treating and preventing bronchospasm—the tightening of airways—in patients who have a reversible obstructive airway disease.

Q: Why do some people experience dry mouth after starting Brusal?

A: While dry mouth is not listed as a common effect in all primary regulatory documents, other adverse events such as throat irritation are noted in the safety profile. Regulatory documents do not offer a specific reason for why some individuals might experience this symptom.

Q: Does Brusal affect the liver or kidney function?

A: Official regulatory documents note that Brusal's active ingredient is largely excreted by the kidney. As a result, the risk of toxic reactions may be greater in patients who have impaired renal function (kidney disease). Regulatory documents primarily focus on the elimination through the kidneys.

Q: Is the Brusal dosage the same for everyone regardless of weight?

A: A physician determines the appropriate dose for each patient based on their age and specific condition. The fact that a lower initial dose may be specified for sensitive groups, such as older adults, indicates that the dose is individualized based on specific patient factors.

How should Brusal be stored and disposed of?

How to Store and Dispose of Brusal?

Official regulatory labeling dictates specific conditions for storing and disposing of Brusal to maintain its quality and potency.


Storage Requirements

Condition Requirement
Temperature Store below 25°C. Do not freeze.
Protection Keep in the original container to protect from light and moisture.
Handling Keep Brusal out of the sight and reach of children.
In-Use Stability If applicable, use within the number of days specified on the official label after the container is first opened or prepared.

Disposal Instructions

Dispose of any unused or expired Brusal and its packaging strictly according to local, state, and federal pharmaceutical waste regulations. Regulatory agencies typically advise against discarding this medicine in household trash or flushing it down a toilet or drain to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Brusal found in:

A-Z Index: